Download PDF
Am J Perinatol
DOI: 10.1055/a-1976-2142
Original Article

Insulin for Treatment of Neonatal Hyperglycemia in Premature Infants: Prevalence over Time and Association with Outcomes

Daniela Titchiner
1   Division of Neonatology, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina
,
Chi Hornik
1   Division of Neonatology, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina
2   Duke Clinical Research Institute, Durham, North Carolina
,
Robert Benjamin
3   Division of Endocrinology, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina
,
Veeral Tolia
4   The MEDNAX Center for Research, Education, Quality and Safety, Sunrise, Florida
5   Division of Neonatology, Department of Pediatrics, Baylor University Medical Center, Dallas, Texas
,
P Brian Smith
1   Division of Neonatology, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina
2   Duke Clinical Research Institute, Durham, North Carolina
,
Rachel G. Greenberg 
1   Division of Neonatology, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina
2   Duke Clinical Research Institute, Durham, North Carolina
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Objective Our objective was to determine the prevalence of insulin treatment in premature infants with hyperglycemia and evaluate the association of length of treatment with outcomes.

Study Design The study included cohort of 29,974 infants 22 to 32 weeks gestational age (GA) admitted to over 300 neonatal intensive care unit (NICU) from 1997 to 2018 and diagnosed with hyperglycemia.

Results Use of insulin significantly decreased during the study period (p = 0.002) among studied NICUs. The percentage of hyperglycemic infants exposed to insulin ranged from 0 to 81%. Infants who received insulin were more likely to have lower GA, birth weight, 5-minute Apgar score, longer duration of stay, and require mechanical ventilation. After adjustment for GA, infants requiring insulin for >14 days were more likely to have treated retinopathy of prematurity (ROP) and develop chronic lung disease (CLD). Insulin treatment of 1 to 7 days had increased odds of death, death/ROP, and death/CLD compared with no exposure.

Conclusion Insulin use decreased over time, and differing durations of use were associated with adverse outcomes.

Key Points

  • Insulin use decreased over time.

  • There is a temporal relation between the duration of treatment and adverse outcomes.

  • Further studies are needed to determine the efficacy and safety of insulin use.

Keywords

insulin - neonates - hyperglycemia - NICU

Supplementary Material



Publication History

Received: 16 April 2022

Accepted: 02 November 2022

Accepted Manuscript online:
10 November 2022

Article published online:
21 December 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Hays SP, Smith EO, Sunehag AL. Hyperglycemia is a risk factor for early death and morbidity in extremely low birth-weight infants. Pediatrics 2006; 118 (05) 1811-1818
    CrossrefPubMedGoogle Scholar
  • 2 Blanco CL, Baillargeon JG, Morrison RL, Gong AK. Hyperglycemia in extremely low birth weight infants in a predominantly Hispanic population and related morbidities. J Perinatol 2006; 26 (12) 737-741
    CrossrefPubMedGoogle Scholar
  • 3 Falcão MC, Ramos JL. [Hyperglycemia and glucosuria in preterm infants receiving parenteral glucose: influence of birth weight, gestational age and infusion rate]. J Pediatr (Rio J) 1998; 74 (05) 389-396
    CrossrefPubMedGoogle Scholar
  • 4 Louik C, Mitchell AA, Epstein MF, Shapiro S. Risk factors for neonatal hyperglycemia associated with 10% dextrose infusion. Am J Dis Child 1985; 139 (08) 783-786
    PubMedGoogle Scholar
  • 5 Grasso S, Distefano G, Messina A, Vigo R, Reitano G. Effect of glucose priming on insulin response in the premature infant. Diabetes 1975; 24 (03) 291-294
    CrossrefPubMedGoogle Scholar
  • 6 Ktorza A, Bihoreau MT, Nurjhan N, Picon L, Girard J. Insulin and glucagon during the perinatal period: secretion and metabolic effects on the liver. Biol Neonate 1985; 48 (04) 204-220
    CrossrefPubMedGoogle Scholar
  • 7 Gruenwald P. HOANG NGOC MINH. Evaluation of body and organ weights in perinatal pathology. I. Normal standards derived from autopsies. Am J Clin Pathol 1960; 34: 247-253
    CrossrefPubMedGoogle Scholar
  • 8 Beardsall K. Hyperglycaemia in the newborn infant. Physiology verses pathology. Front Pediatr 2021; 9: 641306
    CrossrefPubMedGoogle Scholar
  • 9 Sunehag A, Gustafsson J, Ewald U. Very immature infants (< or = 30 Wk) respond to glucose infusion with incomplete suppression of glucose production. Pediatr Res 1994; 36 (04) 550-555
    CrossrefPubMedGoogle Scholar
  • 10 Kashyap S, Polin RA. Insulin infusions in very-low-birth-weight infants. N Engl J Med 2008; 359 (18) 1951-1953
    CrossrefPubMedGoogle Scholar
  • 11 Meetze W, Bowsher R, Compton J, Moorehead H. Hyperglycemia in extremely- low-birth-weight infants. Biol Neonate 1998; 74 (03) 214-221
    CrossrefPubMedGoogle Scholar
  • 12 van den Berghe G, Wouters P, Weekers F. et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345 (19) 1359-1367
    CrossrefPubMedGoogle Scholar
  • 13 Kao LS, Morris BH, Lally KP, Stewart CD, Huseby V, Kennedy KA. Hyperglycemia and morbidity and mortality in extremely low birth weight infants. J Perinatol 2006; 26 (12) 730-736
    CrossrefPubMedGoogle Scholar
  • 14 Pertierra-Cortada A, Ramon-Krauel M, Iriondo-Sanz M, Iglesias-Platas I. Instability of glucose values in very preterm babies at term postmenstrual age. J Pediatr 2014; 165 (06) 1146-1153.e2
    CrossrefPubMedGoogle Scholar
  • 15 Zamir I, Tornevi A, Abrahamsson T. et al. Hyperglycemia in extremely preterm infants-insulin treatment, mortality and nutrient intakes. J Pediatr 2018; 200: 104-110.e1
    CrossrefPubMedGoogle Scholar
  • 16 Spitzer AR, Ellsbury DL, Handler D, Clark RH. The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system—tools for “meaningful use” in continuous quality improvement. Clin Perinatol 2010; 37 (01) 49-70
    CrossrefPubMedGoogle Scholar
  • 17 Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL. , et al. , Prevalence and determinants of hyperglycemia in very low birth weight infants: cohort analyses of the NIRTURE study. J Pediatr 2010; 157 (05) 715-719.e1–3
    CrossrefPubMedGoogle Scholar
  • 18 Szymońska I, Jagła M, Starzec K, Hrnciar K, Kwinta P. The incidence of hyperglycaemia in very low birth weight preterm newborns. Results of a continuous glucose monitoring study—preliminary report. Med Wieku Rozwoj 2015; 19 (3, pt. 1): 305-312
    PubMedGoogle Scholar
  • 19 Ogilvy-Stuart AL, Beardsall K. Management of hyperglycaemia in the preterm infant. Arch Dis Child Fetal Neonatal Ed 2010; 95 (02) F126-F131
    CrossrefPubMedGoogle Scholar
  • 20 Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New intrauterine growth curves based on United States data. Pediatrics 2010; 125 (02) e214-e224
    Google Scholar
  • 21 Engle WA. American Academy of Pediatrics Committee on Fetus and Newborn. Age terminology during the perinatal period. Pediatrics 2004; 114 (05) 1362-1364
    CrossrefPubMedGoogle Scholar
  • 22 Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163 (07) 1723-1729
    Google Scholar
  • 23 Greenberg RG, Gayam S, Savage D. et al; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Furosemide exposure and prevention of bronchopulmonary dysplasia in premature infants. J Pediatr 2019; 208: 134-140.e2
    CrossrefPubMedGoogle Scholar
  • 24 Kumar KR, Clark DA, Kim EM. et al. Association of atrial septal defects and bronchopulmonary dysplasia in premature infants. J Pediatr 2018; 202: 56-62.e2
    CrossrefPubMedGoogle Scholar
  • 25 Lee JH, Greenberg RG, Quek BH. et al. Association between early echocardiography, therapy for patent ductus arteriosus, and outcomes in very low birth weight infants. Cardiol Young 2017; 27 (09) 1732-1739
    CrossrefPubMedGoogle Scholar
  • 26 Kelly MS, Benjamin DK, Puopolo KM. et al. Postnatal cytomegalovirus infection and the risk for bronchopulmonary dysplasia. JAMA Pediatr 2015; 169 (12) e153785
    CrossrefPubMedGoogle Scholar
  • 27 Trembath A, Hornik CP, Clark R, Smith PB, Daniels J, Laughon M. Best Pharmaceuticals for Children Act—Pediatric Trials Network. Comparative effectiveness of surfactant preparations in premature infants. J Pediatr 2013; 163 (04) 955-60.e1
    CrossrefPubMedGoogle Scholar
  • 28 Davidson LM, Berkelhamer SK. Bronchopulmonary dysplasia: chronic lung disease of infancy and long-term pulmonary outcomes. J Clin Med 2017; 6 (01) 4
    CrossrefPubMedGoogle Scholar
  • 29 Hornik CP, Benjamin DK, Becker KC. et al. Use of the complete blood cell count in late-onset neonatal sepsis. Pediatr Infect Dis J 2012; 31 (08) 803-807
    CrossrefPubMedGoogle Scholar
  • 30 Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985; 4 (01) 87-90
    CrossrefPubMedGoogle Scholar
  • 31 Collins Jr JW, Hoppe M, Brown K, Edidin DV, Padbury J, Ogata ES. A controlled trial of insulin infusion and parenteral nutrition in extremely low birth weight infants with glucose intolerance. J Pediatr 1991; 118 (06) 921-927
    CrossrefPubMedGoogle Scholar
  • 32 Kairamkonda VR, Khashu M. Controversies in the management of hyperglycemia in the ELBW infant. Indian Pediatr 2008; 45 (01) 29-38
    PubMedGoogle Scholar
  • 33 Sinclair JC, Bottino M, Cowett RM. Interventions for prevention of neonatal hyperglycemia in very low birth weight infants. Cochrane Database Syst Rev 2011; (10) CD007615
    PubMedGoogle Scholar
  • 34 Tottman AC, Alsweiler JM, Bloomfield FH, Pan M, Harding JE. Relationship between measures of neonatal glycemia, neonatal illness, and 2-year outcomes in very preterm infants. J Pediatr 2017; 188: 115-121
    CrossrefPubMedGoogle Scholar
  • 35 van der Lugt NM, Smits-Wintjens VE, van Zwieten PH, Walther FJ. Short and long term outcome of neonatal hyperglycemia in very preterm infants: a retrospective follow-up study. BMC Pediatr 2010; 10 (01) 52
    CrossrefPubMedGoogle Scholar
  • 36 Vaucher YE, Walson PD, Morrow III G. Continuous insulin infusion in hyperglycemic, very low birth weight infants. J Pediatr Gastroenterol Nutr 1982; 1 (02) 211-217
    CrossrefPubMedGoogle Scholar
  • 37 Thabet F, Bourgeois J, Guy B, Putet G. Continuous insulin infusion in hyperglycaemic very-low-birth-weight infants receiving parenteral nutrition. Clin Nutr 2003; 22 (06) 545-547
    CrossrefPubMedGoogle Scholar
  • 38 Alsweiler JM, Harding JE, Bloomfield FH. Tight glycemic control with insulin in hyperglycemic preterm babies: a randomized controlled trial. Pediatrics 2012; 129 (04) 639-647
    CrossrefPubMedGoogle Scholar
  • 39 Lucas A, Morley R, Cole TJ. Adverse neurodevelopmental outcome of moderate neonatal hypoglycaemia. BMJ 1988; 297 (6659): 1304-1308
    CrossrefPubMedGoogle Scholar
  • 40 Burns CM, Rutherford MA, Boardman JP, Cowan FM. Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia. Pediatrics 2008; 122 (01) 65-74
    CrossrefPubMedGoogle Scholar
  • 41 Tam EW, Widjaja E, Blaser SI, Macgregor DL, Satodia P, Moore AM. Occipital lobe injury and cortical visual outcomes after neonatal hypoglycemia. Pediatrics 2008; 122 (03) 507-512
    CrossrefPubMedGoogle Scholar
  • 42 Tottman AC, Alsweiler JM, Bloomfield FH. et al; PIANO Study Group. Long-term outcomes of hyperglycemic preterm infants randomized to tight glycemic control. J Pediatr 2018; 193: 68-75.e1
    CrossrefPubMedGoogle Scholar